SERPING1 and neuromyelitis optica: An important role for the complement has been suggested in the pathogenesis of NMO, which has raised interest in the possible use of complement-targeted therapeutics, including eculizumab (a monoclonal antibody targeting complement protein C5) [89] and C1-INH [27].